Latest DNLI reports update at 2024-05-07: 2024-Q1 ∙ 2023-Q4 ∙ 2023-Q1

Denali Therapeutics DNLI

$ 18.67 -1.22%

Denali Therapeutics Balance Sheet 2011-2024 | DNLI

Annual Balance Sheet Denali Therapeutics

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-158 M	-229 M	-	-6.92 M	-77.1 M	-218 M	-39.9 M	-30.7 M	-	-	-	-
Long Term Debt	53 M	58.6 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	7.32 M	5.45 M	4.69 M	3.66 M	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	113 M	82.4 M	6.76 M	7.44 M	48.8 M	-	-	-	-
Total Current Liabilities	364 M	378 M	71.7 M	45.3 M	32.8 M	-	-	-	-	-	-	-
Total Liabilities	418 M	442 M	454 M	158 M	115 M	20.9 M	16.5 M	52.3 M	-	-	-	-
Deferred Revenue	-	27.9 M	23.5 M	18.7 M	11.4 M	-	-	-	-	-	-	-
Retained Earnings	-971 M	-645 M	-354 M	-426 M	-228 M	-192 M	-104 M	-16.9 M	-	-	-	-
Total Assets	1.46 B	1.4 B	1.6 B	553 M	662 M	487 M	271 M	36.7 M	-	-	-	-
Cash and Cash Equivalents	218 M	293 M	509 M	79.4 M	77.1 M	218 M	40.4 M	-	-	-	-	-
Book Value	1.04 B	962 M	1.15 B	395 M	547 M	466 M	255 M	-15.6 M	-	-	-	-
Total Shareholders Equity	1.04 B	962 M	1.15 B	395 M	547 M	466 M	-94.2 M	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Denali Therapeutics

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	43 M	45 M	46.9 M	48.8 M	50.5 M	53 M	55 M	55.5 M	57.1 M	58.6 M	60 M	61.4 M	62.9 M	64.2 M	64.2 M	64.2 M	64.2 M	68.9 M	68.9 M	68.9 M	68.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	126 M	123 M	118 M	119 M	443 M	418 M	416 M	408 M	403 M	442 M	438 M	437 M	443 M	454 M	454 M	454 M	454 M	158 M	158 M	158 M	158 M	115 M	115 M	115 M	115 M	20.9 M	20.9 M	20.9 M	20.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	23 K	-	-	27.9 M	1.32 M	5.76 M	12.9 M	19.9 M	19.9 M	19.9 M	19.9 M	18.7 M	18.7 M	18.7 M	18.7 M	11.4 M	11.4 M	11.4 M	11.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.22 B	-1.12 B	-997 M	-897 M	-1.08 B	-971 M	-872 M	-769 M	-710 M	-645 M	-570 M	-485 M	-424 M	-354 M	-354 M	-354 M	-354 M	-426 M	-426 M	-426 M	-426 M	-228 M	-228 M	-228 M	-228 M	-192 M	-192 M	-192 M	-192 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	1.58 B	1.15 B	1.24 B	1.31 B	1.41 B	1.46 B	1.23 B	1.29 B	1.32 B	1.4 B	1.45 B	1.51 B	1.55 B	1.6 B	1.6 B	1.6 B	1.6 B	553 M	553 M	553 M	553 M	662 M	662 M	662 M	662 M	487 M	487 M	487 M	487 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	60.6 M	127 M	148 M	132 M	69.6 M	218 M	120 M	157 M	106 M	293 M	396 M	487 M	435 M	509 M	507 M	507 M	507 M	79.4 M	79.4 M	79.4 M	79.4 M	77.1 M	77.1 M	77.1 M	77.1 M	218 M	218 M	218 M	218 M	39.9 M	-	-	-	30.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	1.46 B	1.03 B	1.12 B	1.19 B	967 M	1.04 B	811 M	884 M	918 M	962 M	1.01 B	1.07 B	1.11 B	1.15 B	1.15 B	1.15 B	1.15 B	395 M	395 M	395 M	395 M	547 M	547 M	547 M	547 M	466 M	466 M	466 M	466 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	1.46 B	1.03 B	1.12 B	1.19 B	967 M	1.04 B	811 M	884 M	918 M	962 M	1.01 B	1.07 B	1.11 B	1.15 B	1.15 B	1.15 B	1.15 B	395 M	395 M	395 M	395 M	547 M	547 M	547 M	547 M	466 M	466 M	466 M	466 M	-94.2 M	-	-	-	-15.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency